These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25958460)

  • 1. [A new approach to the search for vestibuloprotectors].
    Yasnetsov VV; Karsanova SK; Yasnetsov VV
    Aviakosm Ekolog Med; 2015; 49(1):5-12. PubMed ID: 25958460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [VESTIBULAR AND THERMOPROTECTIVE PROPERTIES OF A NEW ACTOPROTECTOR].
    Yasnetsov VV; Tsublova EG; Yasnetsov VV; Skachilova SY; Karsanova SK; Chelnaya NA
    Aviakosm Ekolog Med; 2015; 49(6):29-32. PubMed ID: 26934787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of severe motion sickness with antimotion sickness drug injections.
    Graybiel A; Lackner JR
    Aviat Space Environ Med; 1987 Aug; 58(8):773-6. PubMed ID: 3632537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and duration of intramuscular antimotion sickness medications.
    Wood CD; Stewart JJ; Wood MJ; Mims M
    J Clin Pharmacol; 1992 Nov; 32(11):1008-12. PubMed ID: 1474161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Side effects of antimotion sickness drugs.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood M; Vekovius WA
    Aviat Space Environ Med; 1984 Feb; 55(2):113-6. PubMed ID: 6696702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of vestibuloprotectors mexidol and melatonin on animal cerebellum].
    Iasnetsov VV; Motin VG; Jasnecov VV; Karsanova SK; Ivanov JV; Chel'naja NA
    Aviakosm Ekolog Med; 2014; 48(6):30-3. PubMed ID: 25928981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of antimotion sickness drug side effects on performance.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME
    Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
    Graybiel A; Knepton J; Shaw J
    Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Investigation into the vestibular protective properties of melatoninergic agents].
    Iasnetsov VV; Motin VG; Karsanova SK; Iasnetsov VV; Ivanov IuV; Chel'naia NA
    Aviakosm Ekolog Med; 2014; 48(2):31-4. PubMed ID: 25087409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [On the mechanism of antimotion sickness effects of mexidol].
    Motin VG; Iasnetsov VV
    Aviakosm Ekolog Med; 2010; 44(1):64-6. PubMed ID: 20804002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of motion sickness and antimotion sickness drugs on gastric function.
    Stewart JJ; Wood MJ; Wood CD; Mims ME
    J Clin Pharmacol; 1994 Jun; 34(6):635-43. PubMed ID: 8083395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of anti-motion sickness drugs in the squirrel monkey.
    Cheung BS; Money KE; Kohl RL; Kinter LB
    J Clin Pharmacol; 1992 Feb; 32(2):163-75. PubMed ID: 1613127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological interventions for motion sickness: cardiovascular effects.
    Sunahara FA; Farewell J; Mintz L; Johnson WH
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A270-6. PubMed ID: 3499896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prokinetic effects of erythromycin after antimotion sickness drugs.
    Stewart JJ; Wood MJ; Parish RC; Wood CD
    J Clin Pharmacol; 2000 Apr; 40(4):347-53. PubMed ID: 10761161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of the semicircular canals via the rotary chair as a means to test pharmacologic countermeasures for space motion sickness.
    Dornhoffer J; Chelonis JJ; Blake D
    Otol Neurotol; 2004 Sep; 25(5):740-5. PubMed ID: 15354005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of agomelatine in epilepsy and epileptic complications.
    Vimala PV; Bhutada PS; Patel FR
    Med Hypotheses; 2014 Jan; 82(1):105-10. PubMed ID: 24314750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of antimotion sickness drugs: a new effective remedy revealed.
    Wood CD; Graybiel A
    Aerosp Med; 1970 Aug; 41(8):932-3. PubMed ID: 4988606
    [No Abstract]   [Full Text] [Related]  

  • 19. Various anti-motion sickness drugs and core body temperature changes.
    Cheung B; Nakashima AM; Hofer KD
    Aviat Space Environ Med; 2011 Apr; 82(4):409-15. PubMed ID: 21485398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Motion sickness].
    Naess K
    Tidsskr Nor Laegeforen; 1971 Aug; 91(24):1764-5. PubMed ID: 5111147
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.